A groundbreaking medication , retatrutide, is sparking considerable excitement within the Oz weight control community. Developed by Eli Lilly , this twin GIP and GLP-1 agonist appears to deliver more significant outcomes than current therapies. Initial clinical research have shown remarkable reductions in body mass, suggesting a for a different str